Shimizu Yasuhiro, Suzuki Toshihiro, Yoshikawa Toshiaki, Tsuchiya Nobuhiro, Sawada Yu, Endo Itaru, Nakatsura Tetsuya
Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Cancer Sci. 2018 Mar;109(3):531-541. doi: 10.1111/cas.13485. Epub 2018 Feb 14.
Immune checkpoint inhibitors have ushered in a new era in cancer therapy, although other therapies or combinations thereof are still needed for many patients for whom these drugs are ineffective. In this light, we have identified glypican-3 an HLA-24, HLA-A2 restriction peptide with extreme cancer specificity. In this paper, we summarize results from a number of related clinical trials showing that glypican-3 peptide vaccines induce specific CTLs in most patients (UMIN Clinical Trials Registry: UMIN000001395, UMIN000005093, UMIN000002614, UMN000003696, and UMIN000006357). We also describe the current state of personalized cancer immunotherapy based on neoantigens, and assess, based on our own research and experience, the potential of such therapy to elicit cancer regression. Finally, we discuss the future direction of cancer immunotherapy.
免疫检查点抑制剂开创了癌症治疗的新纪元，不过对于许多这些药物无效的患者而言，仍需要其他疗法或其联合疗法。有鉴于此，我们鉴定出了磷脂酰肌醇蛋白聚糖-3——一种具有极高癌症特异性的HLA-24、HLA-A2限制性肽段。在本文中，我们总结了多项相关临床试验的结果，这些结果表明磷脂酰肌醇蛋白聚糖-3肽疫苗在大多数患者中可诱导特异性细胞毒性T淋巴细胞（UMIN临床试验注册编号：UMIN000001395、UMIN000005093、UMIN000002614、UMN000003696和UMIN000006357）。我们还描述了基于新抗原的个性化癌症免疫疗法的现状，并根据我们自己的研究和经验评估这种疗法引发癌症消退的潜力。最后，我们讨论了癌症免疫疗法的未来方向。
